Incyte's Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific SessionBusiness Wire • 12/11/22
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022Business Wire • 12/10/22
Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical OncologyPRNewsWire • 12/05/22
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast AsiaBusiness Wire • 12/02/22
Incyte (INCY) Up 3.3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/01/22
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid TumorsBusiness Wire • 11/07/22
Data From Incyte's Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingBusiness Wire • 11/07/22
More than 50 Abstracts from Incyte's Robust Oncology Portfolio to be Featured at the 64th ASH Annual MeetingBusiness Wire • 11/03/22
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 11/01/22
Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of MedicineBusiness Wire • 10/19/22
Knight Therapeutics Announces Regulatory Submission for Tafasitamab in BrazilGlobeNewsWire • 10/06/22